Pros and Cons of Medical Management of Ulcerative Colitis

ABSTRACT

Ulcerative colitis (UC) is a chronic inflammatory disease characterized by diffuse mucosal inflammation limited to the colon and rectum. Although a complete medical cure may not be possible, UC can be treated with medications that induce and maintain remission. The medical management of this disease continues to evolve with a goal to avoid colectomy and ultimately alter the natural history of UC. Emergence of antitumor necrosis factor-α (TNF-α) agents has expanded the medical armamentarium. 5-Aminosalicylates continue to be used in mild to moderate UC and corticosteroids are mainly used for induction of remission with immunomodulators (6-mercaptopurine/azathiopurine/methotrexate) being applied as steroid-sparing agents for maintenance therapy. Infliximab has been approved by the U.S. Food and Drug Administration and used in the treatment of moderate to severe UC; nevertheless, its use may be associated with significant adverse effects and have a negative impact on the postoperative course should the patients undergo restorative proctocolectomy. In addition, there is always a concern about patients' compliance to medical therapy, cost of medications, and risk for UC-associated dysplasia. The authors discuss the pros and cons of medications used in the treatment of UC.

KEYWORDS

Inflammatory bowel disease - ulcerative colitis - medical treatment - risks and benefits

REFERENCES

• 1 Meyers S, Janowitz H D. The “natural history” of ulcerative colitis: an analysis of the placebo response.  J Clin Gastroenterol. 1989;  11(1) 33-37
• 2 Loftus Jr E V, Silverstein M D, Sandborn W J, Tremaine W J, Harmsen W S, Zinsmeister A R. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.  Gut. 2000;  46(3) 336-343
• 3 Kappelman M D, Rifas-Shiman S L, Kleinman K et al.. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.  Clin Gastroenterol Hepatol. 2007;  5(12) 1424-1429
• 4 Loftus C G, Loftus Jr E V, Harmsen W S et al.. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.  Inflamm Bowel Dis. 2007;  13(3) 254-261
• 5 Herrinton L J, Liu L, Lewis J D, Griffin P M, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.  Am J Gastroenterol. 2008;  103(8) 1998-2006
• 6 Herrinton L J, Liu L, Lafata J E et al.. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings.  Inflamm Bowel Dis. 2007;  13(4) 451-461
• 7 Sonnenberg A, Chang J. Time trends of physician visits for Crohn's disease and ulcerative colitis in the United States, 1960-2006.  Inflamm Bowel Dis. 2008;  14(2) 249-252
• 8 Nguyen G C, Tuskey A, Dassopoulos T, Harris M L, Brant S R. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004.  Inflamm Bowel Dis. 2007;  13(12) 1529-1535
• 9 Kappelman M D, Rifas-Shiman S L, Porter C Q et al.. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.  Gastroenterology. 2008;  135(6) 1907-1913
• 10 Edwards F C, Truelove S C. The course and prognosis of ulcerative colitis.  Gut. 1963;  4 299-315
• 11 Moum B, Vatn M H, Ekbom A Southeastern Norway IBD Study Group of Gastroenterologists et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration.  Digestion. 1995;  56(5) 377-381
• 12 Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years.  Gastroenterology. 1994;  107(1) 3-11
• 13 Langholz E, Munkholm P, Davidsen M, Nielsen O H, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors.  Scand J Gastroenterol. 1996;  31(3) 260-266
• 14 Sandborn W J, Rutgeerts P, Feagan B G et al.. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.  Gastroenterology. 2009;  137(4) 1250-1260 quiz 1520
• 15 Sutherland L, Macdonald J K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.  Cochrane Database Syst Rev. 2006;  (2) CD000543
• 16 Carter M J, Lobo A J, Travis S P. IBD Section, British Society of Gastroenterology . Guidelines for the management of inflammatory bowel disease in adults.  Gut. 2004;  53(Suppl 5) V1-V16
• 17 Lichtenstein G R, Kamm M A. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis—methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.  Aliment Pharmacol Ther. 2008;  28(6) 663-673
• 18 Lichtenstein G R, Kamm M A, Sandborn W J, Lyne A, Joseph R E. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.  Aliment Pharmacol Ther. 2008;  27(11) 1094-1102
• 19 Rao S S, Dundas S A, Holdsworth C D, Cann P A, Palmer K R, Corbett C L. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.  Gut. 1989;  30(5) 675-679
• 20 Dick A P, Grayson M J, Carpenter R G, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis.  Gut. 1964;  5 437-442
• 21 Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.  Dig Dis Sci. 2009;  54(6) 1157-1170
• 22 Marshall J K, Irvine E J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.  Am J Gastroenterol. 2000;  95(7) 1628-1636
• 23 Lee F I, Jewell D P, Mani V et al.. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.  Gut. 1996;  38(2) 229-233
• 24 Regueiro M, Loftus Jr E V, Steinhart A H, Cohen R D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.  Inflamm Bowel Dis. 2006;  12(10) 979-994
• 25 Safdi M, DeMicco M, Sninsky C et al.. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.  Am J Gastroenterol. 1997;  92(10) 1867-1871
• 26 Moss A C, Peppercorn M A. The risks and the benefits of mesalazine as a treatment for ulcerative colitis.  Expert Opin Drug Saf. 2007;  6(2) 99-107
• 27 Hanauer S B, Sandborn W J, Dallaire C et al.. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.  Can J Gastroenterol. 2007;  21(12) 827-834
• 28 Kamm M A, Sandborn W J, Gassull M et al.. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.  Gastroenterology. 2007;  132(1) 66-75 quiz 432-433
• 29 Lichtenstein G R, Kamm M A, Boddu P et al.. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.  Clin Gastroenterol Hepatol. 2007;  5(1) 95-102
• 30 Sandborn W J, Kamm M A, Lichtenstein G R, Lyne A, Butler T, Joseph R E. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.  Aliment Pharmacol Ther. 2007;  26(2) 205-215
• 31 Marteau P, Probert C S, Lindgren S et al.. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.  Gut. 2005;  54(7) 960-965
• 32 Kamm M A, Lichtenstein G R, Sandborn W J et al.. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.  Gut. 2008;  57(7) 893-902
• 33 Kruis W, Kiudelis G, Rácz I International Salofalk OD Study Group et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.  Gut. 2009;  58(2) 233-240
• 34 Kruis W, Jonaitis L, Pokrotnieks J et al.. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose ranging study.  Gastroenterology. 2008;  134(Suppl 1) A489
• 35 Prescribing information for Apriso (extended release mesalamine). Morrisville, NC; Salix Pharmaceuticals, Inc 2009
• 36 Velayos F S, Terdiman J P, Walsh J M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.  Am J Gastroenterol. 2005;  100(6) 1345-1353
• 37 Levine J S, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.  Inflamm Bowel Dis. 2007;  13(10) 1293-1298
• 38 James S L, Irving P M, Gearry R B, Gibson P R. Management of distal ulcerative colitis: frequently asked questions analysis.  Intern Med J. 2008;  38(2) 114-119
• 39 Lémann M, Galian A, Rutgeerts P et al.. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis.  Aliment Pharmacol Ther. 1995;  9(5) 557-562
• 40 Faubion Jr W A, Loftus Jr E V, Harmsen W S, Zinsmeister A R, Sandborn W J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.  Gastroenterology. 2001;  121(2) 255-260
• 41 Truelove S C, Willoughby C P, Lee E G, Kettlewell M G. Further experience in the treatment of severe attacks of ulcerative colitis.  Lancet. 1978;  2(8099) 1086-1088
• 42 Ng S C, Kamm M A. Therapeutic strategies for the management of ulcerative colitis.  Inflamm Bowel Dis. 2009;  15(6) 935-950
• 43 Löfberg R, Danielsson A, Suhr O et al.. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.  Gastroenterology. 1996;  110(6) 1713-1718
• 44 Pearson D C, May G R, Fick G H, Sutherland L R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.  Ann Intern Med. 1995;  123(2) 132-142
• 45 Black A J, McLeod H L, Capell H A et al.. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.  Ann Intern Med. 1998;  129(9) 716-718
• 46 Snow J L, Gibson L E. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients.  J Am Acad Dermatol. 1995;  32(1) 114-116
• 47 Hawthorne A B, Logan R F, Hawkey C J et al.. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.  BMJ. 1992;  305(6844) 20-22
• 48 Adler D J, Korelitz B I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis.  Am J Gastroenterol. 1990;  85(6) 717-722
• 49 George J, Present D H, Pou R, Bodian C, Rubin P H. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.  Am J Gastroenterol. 1996;  91(9) 1711-1714
• 50 Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis.  J Clin Gastroenterol. 1997;  25(1) 330-333
• 51 Lobo A J, Foster P N, Burke D A, Johnston D, Axon A T. The role of azathioprine in the management of ulcerative colitis.  Dis Colon Rectum. 1990;  33(5) 374-377
• 52 Karoui S, Djebbi S, Belkhodja A, Boubaker J, Filali A. [Maintenance therapy by azathioprine after successful treatment by intravenous corticosteroid in acute severe colitis. An open prospective study].  Tunis Med. 2008;  86(4) 322-327
• 53 Timmer A, McDonald J W, Macdonald J K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.  Cochrane Database Syst Rev. 2007;  (1) CD000478
• 54 Mantzaris G J, Sfakianakis M, Archavlis E et al.. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.  Am J Gastroenterol. 2004;  99(6) 1122-1128
• 55 Gisbert J P, Linares P M, McNicholl A G, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis.  Aliment Pharmacol Ther. 2009;  30(2) 126-137
• 56 Lichtenstein G R, Abreu M T, Cohen R, Tremaine W. American Gastroenterological Association . American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.  Gastroenterology. 2006;  130(3) 940-987
• 57 Lichtiger S, Present D H, Kornbluth A et al.. Cyclosporine in severe ulcerative colitis refractory to steroid therapy.  N Engl J Med. 1994;  330(26) 1841-1845
• 58 D'Haens G, Lemmens L, Geboes K et al.. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.  Gastroenterology. 2001;  120(6) 1323-1329
• 59 Svavoni F, Bonassi U, Bagnolo F et al.. Effectiveness of cyclosporine (CsA) in the treatment of refractory ulcerative colitis (UC).  Gastroenterology. 1998;  114 A1096
• 60 Van Assche G, D'Haens G, Noman M et al.. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.  Gastroenterology. 2003;  125(4) 1025-1031
• 61 Moskovitz D N, Van Assche G, Maenhout B et al.. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.  Clin Gastroenterol Hepatol. 2006;  4(6) 760-765
• 62 Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis.  Cochrane Database Syst Rev. 2005;  (1) CD004277
• 63 Shah S B, Parekh N K, Hanauer S B et al.. Intravenous cyclosporine in severe steroid-refractory ulcerative colitis: long term follow-up.  Gastroenterology. 2008;  134(Suppl 1) 133
• 64 Cohen R D, Brodsky A L, Hanauer S B. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin.  Inflamm Bowel Dis. 1999;  5(1) 1-10
• 65 Arts J, D'Haens G, Zeegers M et al.. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.  Inflamm Bowel Dis. 2004;  10(2) 73-78
• 66 Rayner C K, McCormack G, Emmanuel A V, Kamm M A. Long-term results of low-dose intravenous cyclosporin for acute severe ulcerative colitis.  Aliment Pharmacol Ther. 2003;  18(3) 303-308
• 67 Chey W Y. Infliximab for patients with refractory ulcerative colitis.  Inflamm Bowel Dis. 2001;  7(Suppl 1) S30-S33
• 68 Chey W Y, Hussain A, Ryan C, Potter G D, Shah A. Infliximab for refractory ulcerative colitis.  Am J Gastroenterol. 2001;  96(8) 2373-2381
• 69 Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study.  Wien Klin Wochenschr. 2001;  113(23-24) 930-933
• 70 Su C, Salzberg B A, Lewis J D et al.. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.  Am J Gastroenterol. 2002;  97(10) 2577-2584
• 71 Gornet J M, Couve S, Hassani Z et al.. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.  Aliment Pharmacol Ther. 2003;  18(2) 175-181
• 72 Sands B E, Tremaine W J, Sandborn W J et al.. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.  Inflamm Bowel Dis. 2001;  7(2) 83-88
• 73 Järnerot G, Hertervig E, Friis-Liby I et al.. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.  Gastroenterology. 2005;  128(7) 1805-1811
• 74 Probert C S, Hearing S D, Schreiber S et al.. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.  Gut. 2003;  52(7) 998-1002
• 75 Rutgeerts P, Sandborn W J, Feagan B G et al.. Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med. 2005;  353(23) 2462-2476
• 76 Feagan B G, Reinisch W, Rutgeerts P et al.. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.  Am J Gastroenterol. 2007;  102(4) 794-802
• 77 Aratari A, Papi C, Clemente V et al.. Colectomy rate in acute severe ulcerative colitis in the infliximab era.  Dig Liver Dis. 2008;  40(10) 821-826
• 78 Kariv R, Remzi F H, Lian L et al.. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy.  Gastroenterology. 2010;  139(3) 806-812
• 79 D'Haens G, Baert F, van Assche G Belgian Inflammatory Bowel Disease Research Group et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.  Lancet. 2008;  371(9613) 660-667
• 80 Kane S V, Cohen R D, Aikens J E, Hanauer S B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.  Am J Gastroenterol. 2001;  96(10) 2929-2933
• 81 Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos P L, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis.  Inflamm Bowel Dis. 2007;  13(10) 1244-1249
• 82 Sewitch M J, Abrahamowicz M, Barkun A et al.. Patient nonadherence to medication in inflammatory bowel disease.  Am J Gastroenterol. 2003;  98(7) 1535-1544
• 83 Bernal I, Domènech E, Garcia-Planella E et al.. Medication-taking behavior in a cohort of patients with inflammatory bowel disease.  Dig Dis Sci. 2006;  51(12) 2165-2169
• 84 Mackner L M, Crandall W V. Oral medication adherence in pediatric inflammatory bowel disease.  Inflamm Bowel Dis. 2005;  11(11) 1006-1012
• 85 Oliva-Hemker M M, Abadom V, Cuffari C, Thompson R E. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease.  J Pediatr Gastroenterol Nutr. 2007;  44(2) 180-184
• 86 Wright S, Sanders D S, Lobo A J, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.  Gut. 2004;  53(8) 1123-1128
• 87 Mantzaris G J, Sfakianakis M, Archavlis E et al.. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.  Am J Gastroenterol. 2004;  99(6) 1122-1128
• 88 Kane S V, Aikens J E, Huo D, Hanauer S B. Medication adherence is associated with improved outcomes in patients with quiescent ulcerative colitis.  Am J Med. 2003;  114 39-43
• 89 Mahadevan U. Medical treatment of ulcerative colitis.  Clin Colon Rectal Surg. 2004;  17(1) 7-19
• 90 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.  Inflamm Bowel Dis. 2010;  16(9) 1598-1619 , [Epub ahead of print]
• 91 Farrell G C. Drug-Induced Liver Disease. 1st ed. Singapore; Churchill Livingstone 1994
• 92 Mardini H E. Azathioprine-induced pancreatitis in Crohn's disease: a smoking gun or guilt by association.  Aliment Pharmacol Ther. 2005;  21(2) 195
• 93 Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease.  Gut. 2008;  57(12) 1639-1641
• 94 Lichtenstein G R, Feagan B, Cohen R D et al.. Risk factors for serious infections in patients receiving infliximab and other Crohn's disease therapies: TREAT registry data.  Gastroenterology. 2010;  38(Suppl 1) 475
• 95 Selvasekar C R, Cima R R, Larson D W et al.. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.  J Am Coll Surg. 2007;  204(5) 956-962 discussion 962-963
• 96 Mor I J, Vogel J D, da Luz Moreira A, Shen B, Hammel J, Remzi F H. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy.  Dis Colon Rectum. 2008;  51(8) 1202-1207 discussion 1207-1210
• 97 Chaparro M, Burgueno P, Flores E et al.. Efficacy and safety of infliximab rescue therapy after cyclosporine failure in patients with steroid-refractory ulcerative colitis: a multicenter study.  Gastroenterology. 2010;  38(Suppl) 688
• 98 Järnerot G. Fertility, sterility, and pregnancy in chronic inflammatory bowel disease.  Scand J Gastroenterol. 1982;  17(1) 1-4
• 99 Narendranathan M, Sandler R S, Suchindran C M, Savitz D A. Male infertility in inflammatory bowel disease.  J Clin Gastroenterol. 1989;  11(4) 403-406
• 100 Toovey S, Hudson E, Hendry W F, Levi A J. Sulphasalazine and male infertility: reversibility and possible mechanism.  Gut. 1981;  22(6) 445-451
• 101 Moody G A, Probert C, Jayanthi V, Mayberry J F. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire.  Int J Colorectal Dis. 1997;  12(4) 220-224
• 102 Dejaco C MC, Mittermaier C, Reinisch W et al.. Azathioprine treatment and male fertility in inflammatory bowel disease.  Gastroenterology. 2001;  121(5) 1048-1053
• 103 Mahadevan U, Terdiman J P, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease.  Inflamm Bowel Dis. 2005;  11(4) 395-399
• 104 Dominitz J A, Young J C, Boyko E J. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study.  Am J Gastroenterol. 2002;  97(3) 641-648
• 105 Nørgård B, Fonager K, Pedersen L, Jacobsen B A, Sørensen H T. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study.  Gut. 2003;  52(2) 243-247
• 106 Nørgård B, Pedersen L, Fonager K, Rasmussen S N, Sørensen H T. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study.  Aliment Pharmacol Ther. 2003;  17(6) 827-834
• 107 Eaden J A, Abrams K R, Mayberry J F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis.  Gut. 2001;  48(4) 526-535
• 108 Choi P M, Nugent F W, Schoetz Jr D J, Silverman M L, Haggitt R C. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.  Gastroenterology. 1993;  105(2) 418-424
• 109 Lynch D A, Lobo A J, Sobala G M, Dixon M F, Axon A T. Failure of colonoscopic surveillance in ulcerative colitis.  Gut. 1993;  34(8) 1075-1080
• 110 Sonnenberg A, El-Serag H B. Economic aspects of endoscopic screening for intestinal precancerous conditions.  Gastrointest Endosc Clin N Am. 1997;  7(1) 165-184
• 111 Collins Jr R H, Feldman M, Fordtran J S. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review.  N Engl J Med. 1987;  316(26) 1654-1658
• 112 Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease: ulcerative colitis.  J Clin Gastroenterol. 2001;  32(2) 99-105
• 113 Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.  Gastroenterology. 1994;  107(1) 117-120
• 114 Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study.  Aliment Pharmacol Ther. 2000;  14(2) 145-153
• 115 Velayos F S, Terdiman J P, Walsh J M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.  Am J Gastroenterol. 2005;  100(6) 1345-1353
• 116 Kornbluth A, Sachar D B. Practice Parameters Committee of the American College of Gastroenterology . Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee.  Am J Gastroenterol. 2010;  105(3) 501-523, quiz 524
• 117 Woolrich A J, DaSilva M D, Korelitz B I. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia.  Gastroenterology. 1992;  103(2) 431-438
• 118 Winawer S, Fletcher R, Rex D Gastrointestinal Consortium Panel et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.  Gastroenterology. 2003;  124(2) 544-560
• 119 Camilleri-Brennan J, Steele R J. Objective assessment of quality of life following panproctocolectomy and ileostomy for ulcerative colitis.  Ann R Coll Surg Engl. 2001;  83(5) 321-324
• 120 Carmon E, Keidar A, Ravid A, Goldman G, Rabau M. The correlation between quality of life and functional outcome in ulcerative colitis patients after proctocolectomy ileal pouch anal anastomosis.  Colorectal Dis. 2003;  5(3) 228-232
• 121 Fazio V W, O'Riordain M G, Lavery I C et al.. Long-term functional outcome and quality of life after stapled restorative proctocolectomy.  Ann Surg. 1999;  230(4) 575-584 discussion 584-586
• 122 Thirlby R C, Sobrino M A, Randall J B. The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease.  Arch Surg. 2001;  136(5) 521-527
• 123 Berndtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis—a prospective study.  Colorectal Dis. 2003;  5(2) 173-179
• 124 Martin A, Dinca M, Leone L et al.. Quality of life after proctocolectomy and ileo-anal anastomosis for severe ulcerative colitis.  Am J Gastroenterol. 1998;  93(2) 166-169
• 125 Parks A G, Nicholls R J. Proctocolectomy without ileostomy for ulcerative colitis.  BMJ. 1978;  2(6130) 85-88
• 126 McLeod R S, Baxter N N. Quality of life of patients with inflammatory bowel disease after surgery.  World J Surg. 1998;  22(4) 375-381